Conditions: Gout and Hyperuricemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 204
Healthy volunteers: no

Brief summary:
This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in greater reduction of sUA compared to placebo.

Detailed description:

Arms:
arm 1: RDEA3170 5mg followed by RDEA3170 7.5mg arm 2: RDEA3170 10mg followed by RDEA3170 12.5mg arm 3: RDEA3170 12.5mg followed by RDEA3170 15mg arm 4: RDEA3170 Placebo arm 5: Allopurinol 200mg

Interventions: intervention 1: RDEA3170 intervention 2: Allopurinol intervention 3: Placebo
Intervention descriptions: intervention 1: Oral Treatment intervention 2: Oral Treatment intervention 3: Oral Treatment

Protocol document: